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Summary: Background: Biomarkers of vascular diseases such as ankle-brachial index (ABI), peripheral pulse pressure (pPP), 
central pulse pressure (cPP), and pulse wave velocity (PWV) allow assessment of arterial organ damage (AOD). However, the 
utility of markers other than ABI in patients with peripheral arterial disease (PAD), which are also associated with a signiﬁ -
cant increase of cardiovascular events, remains unclear. Patients and methods: Asymptomatic (n  =  21) and symptomatic 
patients (n = 46) with a positive sonography for PAD or history of lower limb revascularization were included. ABI, pPP, cPP, 
and PWV were assessed. PWV were performed using a brachial cuff-based method (aortic PWV (aPWV)) and oscillography 
(carotid-femoral pulse wave velocity (cfPWV)), respectively. The two methods for PWV were compared using Bland Altman 
analysis. Sensitivities of ABI, pPP, cPP, cfPWV, and aPWV for AOD were calculated. Results: Sixty-seven patients (35.8 % fe-
male, mean age 69, range 39–91 years) had a signiﬁ cantly higher aPWV than cfPWV (median 10.5 m/s (IQR: 8.8–12.65 m/s) vs. 
median 9.0 m/s (IQR: 7.57–10.55 m/s), p = 0.0013). There was no correlation between cfPWV and age (r = 0.311, p = 0.116). 
Bland Altman analysis revealed a mean difference of -1.04 (-2SD; -6.38 to + 2SD; 4.31). The sensitivities for AOD were 68.7 % 
for ABI, 61.2 % for aPWV, 40.3 % for cfPWV, 31.3 % for peripheral PP, and 10.4 % for central aortic PP (p < 0.001). Conclusions: 
Brachial-derived aPWV differs from the gold standard assessment (cfPWV), which may be underestimated in PAD due to ath-
erosclerotic obstructions along the aorto-iliac segment. The sensitivities of noninvasive in vivo markers of AOD vary widely 
and tend to underestimate the actual presence of AOD.
Keywords: Pulse wave velocity, arterial organ damage, peripheral arterial disease, pulse pressure
tine clinical setting using a number of commercially avail-
able devices, making it an attractive in vivo marker of vas-
cular disease. In addition, assessment of arterial organ 
damage (AOD), for example through ABI and PWV, has 
been proposed in asymptomatic individuals by the latest 
guidelines of the European Societies of Hypertension and 
Cardiology (ESH/ESC) [9]. A large body of evidence indi-
cates that AOD plays a crucial role in determining the 
CV risk of asymptomatic individuals [8–10]. Vascular in 
vivo markers such as ABI index (ABI < 0.9), peripheral/
central pulse pressure (pPP/cPP > 60  mmHg) and cfPWV 
(> 10m/s) are used to assess AOD according to guidelines 
[9, 10]. Atherosclerosis is irreversible. Early atherosclero-
sis is asymptomatic and associated with a markedly in-
creased risk for coronary and cerebrovascular events [11]. 
Hence, peripheral arterial disease (PAD) is an overt AOD, 
which should be detec table by the assessment of the 
abovementioned markers of vascular disease. We hypoth-
Introduction
Arterial stiff ness is an important and independent risk fac-
tor for cardiovascular events (CV) [1–3]. The assessment of 
arterial stiff ness has gained substantial importance mostly 
in primary but also secondary prevention as it may guide 
therapy and predict the outcome [4–6]. A current large 
meta-analysis has reported that carotid-femoral pulse 
wave velocity (cfPWV) predicts future cardiovascular risk 
and improves risk classifi cation in addition to established 
risk factors in low and intermediated risk patients in a pri-
mary prevention setting [7]. Aortic stiff ness can be as-
sessed in a number of ways. Carotid-femoral pulse wave 
travelling time currently is regarded as the gold standard 
and has been related to increased cardiovascular risks. 
However, aortic pulse wave velocity (aPWV), derived from 
[8, 9] carotid-femoral pulse wave travelling time, has not 
been studied extensively. PWV can be assessed in a rou-
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esized that cfPWV may not be appropriate to detect AOD 
in PAD due to atherosclerotic obstruction along the aorto-
iliac segments. We therefore assessed PWV with two dif-
ferent commercially available devices and tested and com-
pared sensitivities of PWV, cPP, pPP, and ABI to detect 
AOD in selected, well-defi ned patients with PAD.
Patients and methods
The study was conducted at the University Hospital of Zu-
rich, which serves as a tertiary referral centre. ABI, PP (pe-
ripheral and central), and PWV (aortic and carotid-femo-
ral) were assessed in consecutive patients with PAD who 
were either referred for clinical evaluation or follow-up. 
Only patients with chronic and stable PAD were eligible for 
the study. Inclusion criteria were colour-coded duplex so-
nography with plaques > 15 mm or a history of lower limb 
revascularization, which defi ned presence of PAD. Exclu-
sion criteria were critical limb ischaemia (Fontaine IV), car-
diac arrhythmia, and chronic infl ammatory vascular disor-
ders. Patients continued to take their regular medications. 
The presence of coronary and cerebrovascular diseases 
was defi ned by clinical history of either events or interven-
tions. The study was approved by the local ethics commit-
tee and was conducted according to clinical practice stand-
ards [12]. Measurements were part of the standard care, 
including pulse volume recordings for oscillometric assess-
ment of PWV and brachial blood pressure assessment for 
brachial derived PWV. The following data were collected: 
anthropometric data (height, weight), comorbidities and 
medications, major vascular risk factors (arterial hyperten-
sion, diabetes mellitus, dyslipidaemia, and smoking), pe-
ripheral systolic and diastolic blood pressures, heart rate, 
central blood pressures, ABI, cfPWV, and aPWV.
Pulse wave velocity
Pulse wave velocity was measured in all patients using a 
brachial cuff -based method (Mobil-O-Graph; I. E.M., Stol-
berg, Germany) and an oscillometric device (Vicorder; 
Skidmore Medical, Bristol, UK). Patients rested in a supine 
position for 10 Minutes in a quiet room. AOD was defi ned 
according to the ESH/ESC guidelines for the management 
of arterial hypertension as a PWV > 10 m/s [9]. All meas-
urements were carried out in triplicate by the same vascu-
lar technicians and mean values of the triplicate measure-
ments were calculated and used for analysis.
Mobil-O-Graph
The ARCSolver method, on which the Mobil-O-Graph 
measurement is based, performs pulse wave analysis 
based on oscillometric blood pressure measurements with 
a common blood pressure cuff . The method was developed 
by the Austrian Institute of Technology in Vienna and uses 
the pulse waves assessed at the brachial artery level [13]. 
Simplifi cation of the signal processing is performed using 
a three level algorithm. In a fi rst step, the single brachial 
pressure waves are verifi ed for their plausibility, using 
pulse wave analysis and impedance wave separation. 
Thereafter, an aortic pulse wave is generated by means of 
a generalized transfer function [13–18]. The required fl ow 
is approximated by a model-based approach using meth-
ods described by Wassertheurer and Parragh [13, 19]. This 
is an operator-independent method for 24-hour ambula-
tory peripheral and central blood pressure and aortic PWV 
monitoring, invasively validated by Hametner et al. [15].
Vicorder
The Vicorder device allows measurement of carotid to fem-
oral PWV. A collar is placed on the patient’s neck, equipped 
with a photoplethysmographic sensor, which is able to re-
cord carotid pressure waves. A second cuff  is placed around 
the right upper thigh. The carotid and femoral waveforms 
are recorded simultaneously and estimate the transit time 
by means of the foot-to-foot method [16]. The foot point in 
the pressure wave was defi ned as the beginning of systole 
that was identifi ed by an inbuilt algorithm that was centred 
on the peak of the second derivative of pressure [17, 18]. 
Path length was defi ned as the distance from the supraster-
nal notch to the top of the thigh cuff  [17]. The cfPWV was 
calculated as path length divided by the transit time: cfPWV 
(m/s) = path length (m)/transit time (s).
Ankle-brachial index, 
peripheral and central pulse pressure
Standard brachial systolic and diastolic blood pressures on 
both arms with traditional cuff  manometer were measured 
in triplicate according to the Riva Rocci method. Systolic 
ankle blood pressures of the anterior and posterior tibial 
artery on both legs were obtained using a hand-held 6-MHz 
Doppler probe. For each leg, ABI was calculated as the ratio 
of the highest ankle systolic blood pressure divided by the 
highest brachial systolic blood pressure, the lower ABI was 
taken as the study reference [20]. The AOD was defi ned as 
an ABI of < 0.9 or > 1.3 (incompressible tibial and peroneal 
arteries due to mediacalcinosis) according to the ESH/ESC 
guidelines for the management of arterial hypertension [9]. 
Pulse pressure represents the blood pressure amplitude, i. e. 
the diff erence of systolic blood pressure and diastolic blood 
pressure. We applied the peripheral pulse pressure and the 
noninvasive measurements of the central pulse pressure de-
rived from the Mobil-O-Graph [15, 21]. The blood pressure 
(peripheral and central) was carried out in triplicate and 
mean values of the triplicate measurements were calculat-
ed and used for analysis. The AOD was defi ned according to 
the ESH/ESC guidelines for the management of arterial hy-
pertension as a peripheral or central PP > 60 mmHg [9, 15].
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Statistical analysis
Descriptive statistics for continuous variables are given as 
median and interquartile range (IQR). For categorical vari-
ables, results are presented as number and percentages. 
Age, ABI, and pulse pressure were considered as inde-
pendent variables and PWV as a dependent variable. Uni-
variate linear regression by Spearman Rank correlation 
was used to determine the association between cfPWV 
and age and pulse pressure. The two methods for PWV 
were analysed by univariate correlation and by Bland-Alt-
man plot. Values of two-sided tests with p < 0.05 were con-
sidered statistically signifi cant. The McNemar’s test was 
applied to test for sensitivity [22].
Diff erence of sensitivity between in vivo markers of vas-
cular organ damage (ABI, cfPWV, aPWV, pPP, cPP) was 
assessed by Cochran’s Q test [23]. All analyses were per-
formed using StatView software (Abacus, Berkeley, CA, 
U. S.A.) and R: a language and environment for statistical 
computing (the R Foundation for Statistical Computing, 
Vienna, Austria).
Results
Sixty-seven patients (24 women (35.8 %)) with PAD and a 
mean age of 69 years (range 39–91 years) were studied. 
The characteristics of the study population are summa-
rized in Table I. The PWV from the Mobil-O-Graph (medi-
an 10.5 m/s; IQR 8.8–12.7 m/s) were signifi cantly diff erent 
(p  =  0.0013) from the Vicorder (median 9  m/s; IQR 7.6–
10.6 m/s). Figure 1 shows the univariate correlation and the 
Bland-Altman plot for the two devices. The mean diff er-
ence was -1.04 (-2SD, -6.38; + 2SD, 4.31). Correlation with 
age was found for aPWV (Mobil-O-graph) with r  =  0.935 
(p = < 0.0001) but not for the cfPWV (Vicorder) (r = 0.311 
(p  =  0.116)). Figure 2A/2B shows the correlation between 
PWV and peripheral pulse pressures. The correlation coef-
fi cients were r  =  0.606 (p  =  < 0.0001) for pulse pressure 
and aPWV (by Mobil-O-Graph) and r = 0.248 (p = 0.442) 
for pulse pressure and cfPWV (by Vicorder).
Twenty-one (31 %) of a total of 67 patients had a normal 
ABI ranging from 0.9 to 1.3 with a median of 0.98 (IQR 
0.93–1). Forty-one (62 %) patients had an ABI lower than 
0.9 (median 0.6 (IQR: 0.46–0.74), and fi ve (7 %) patients 
had mediacalcinosis with a median ABI of 1.4 (IQR: 1.38–
1.4). Sensitivities for the presence of AOD in relation to 
each of the in vivo markers of arterial organ injury are 
shown in Figure 3. Sensitivities to detect AOD in PAD pa-
tients ranged from 10.4 % (central pulse pressure) to 
68.7 % (ABI). The carotid-femoral PWV, the current gold 
standard, had a sensitivity of 40.3 % for AOD. The sensi-
tivities for AOD between aPWV and cfPWV diff ered sig-
nifi cantly (p  =  0.043) with better sensitivity of aPWV for 
AOD. The diff erence in sensitivities between aPWV and 
ABI were not signifi cant (p = 0.3173). After correction for 
multiple testing, the diff erences between the sensitivities 
of aPWV and cfPWV remained signifi cant (p  =  0.008). 
Cochran’s Q test confi rms that there is strong evidence 
that the fi ve diagnostic tests do not have the same sensitiv-
ity (p < 0.001) [23].
Discussion
In this study we determined the sensitivities of fi ve rele-
vant arterial disease indices or in vivo markers of AOD that 
are all easily applied, noninvasive, and in part automated 
in their use. We found that currently used in vivo markers 
of AOD have a much lower sensitivity to detect vascular 
damage in patients with PAD than expected. This may re-
sult in insuffi  cient detection or underdiagnosed vascular 
damage in PAD using each measurement modality. These 
in vivo markers have gained great attention as screening 
tools for AOD mostly in asymptomatic patients with cardi-
ovascular risk factors in a primary care setting. All param-
eters are based on blood pressure relations (ABI, central 
and peripheral PP) or pulse wave characteristics (aortic 
Table I. Characteristics of 67 patients with peripheral arterial disease.
Age, (yrs) 69 (39–91)
BMI, (kg/m2) 27(17–44)
Blood pressure (mmHg) *  
Systolic 136 (125–153)
Diastolic 82 (75–89)
Peripheral pulse pressure 55 (44–65)
Central pulse pressure  53 ( 42–63)
Ankle brachial index * 0.79 (0.96–0.58)
Pulse wave velocity (m/s) *
Mobil-O-Graph® 10.5 (8.8–12.7)
Vicorder® 9 (7.6–10.6)
Cardiovascular risk factor **  
Diabetes mellitus 21 (31)
Dyslipidaemia 36 (53)
Hypertension 51 (76)
Ever smoking 51 (76)
Positive family history 18 (27)
Cardiovascular comorbidities**  
Coronary artery disease 24 (36)
Cerebrovascular disease 13 (19)
Data are mean (range), *median (interquartile range) or **number 
(percentage).
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and carotid-femoral PWV). As expected, ABI revealed the 
highest sensitivity for AOD. Accordingly, the diff erence 
between upper to lower extremity blood pressure per se is 
the noninvasive diagnostic tool of choice for PAD. We also 
included PAD patients with an ABI within the normal 
range following lower limb angioplasty and found that ABI 
was not pathologic and hence not sensitive to AOD. Unex-
pectedly, cfPWV had a low sensitivity for AOD in PAD and 
even lower than aPWV. As a consequence, aPWV and cfP-
WV measurements did not correlate, revealing higher val-
ues for PWV derived from the brachial artery (aPWV). This 
might be explained by the fact that the brachial artery is 
mostly free of atherosclerotic plaque and thus pulse wave 
Figure 1. A) Regression plot for aortic pulse wave velocity by Mobil-O-Graph® and carotid-femoral pulse wave velocity by Vicorder® in PAD 
(r = 0.339; p = 0.0058). B) Bland-Altman graph of pulse wave velocity (m/s) Mobil-O-Graph® (aortic) vs. Vicorder® (carotid-femoral).
Figure 2. Regression plots for pulse wave velocities and peripheral pulse pressures in patients with peripheral arterial disease by A) Mobil-O-
Graph® (r = 0.606; p = < 0.0001) and B) Vicorder® (r = 0.248; p = 0.442).
Figure 3. Bar graph shows values of sensitivity by the ﬁ ve diagnostic 
tests for arterial organ damage.
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analysis may be more accurate. Unexpectedly, cfPWV was 
not associated with age. This may be explained by the fact 
that atherosclerosis and obstructive lesions along the aor-
tic and iliac arterial segments cause delay in systolic up-
stroke of the wave at the femoral level resulting in a false 
low cfPWV [24]. Therefore, cfPWV can only be reliably 
assessed if relevant atherosclerotic disease is absent be-
tween the carotid and femoral artery. Thus, a comprehen-
sive vascular assessment including imaging prior to a sim-
ple cfPWV assessment, especially in elderly patients and 
those with cardiovascular risk factors, is necessary due to 
the high prevalence of PAD. Alternatively, measurements 
could be performed with the Mobil-O-Graph for the bra-
chial measurement using the ARCSolver, a novel method 
to noninvasively estimate aortic PWV from a single bra-
chial cuff  waveform [13, 25, 26]. Hametner and Was-
sertheurer showed a signifi cant linear correlation between 
the noninvasive assessment and the intraaortic pressure 
measurement [15]. This suggests that the combination 
provides an easily gained approximation for aortic PWV 
with promising results compared to other methods and 
that it might be of use in PAD [23]. Other studies, which 
investigated PWV in PAD using the SphygmoCor device, 
support our fi ndings. Brand et al. investigated 136 patients 
with critical limb ischaemia and 194 controls. They dem-
onstrated that PWV is markedly lower in patients with crit-
ical limb ischaemia (PWV = 5.72 m/s) when compared to 
healthy controls (PWV = 8.62m/s). Similarly, there was no 
correlation between PWV and age [24]. In contrast, Cata-
lano et al. reported higher PWV assessed by SphygmoCor 
in PAD patients than in the control group (11  ±  3  m/s vs. 
9.8 ± 1.8 m/s), which negatively correlated with ABI in the 
PAD group and had no correlation with age (r  =  0.13, 
p = 0.06) [27]. Although these fi ndings can be considered 
confl icting, they indicate that cfPWV should be assessed 
with caution in presence of PAD.
Other parameters that are derived from blood pressure 
measurements are the central aortic and peripheral pres-
sure amplitudes. Arterial stiff ening resulting from aortic 
atherosclerosis or loss of Windkessel function increases 
systolic arterial blood pressure and decreases diastolic 
blood pressures, resulting in an increase in blood pressure 
amplitude, which is a recognized pressure pattern in PAD 
[28, 29]. Despite the fact that the pathophysiology of these 
changes is well understood and documented, the suggest-
ed cut-off  at > 60 mmHg in amplitudes was not suffi  cient 
to identify AOD in the majority of our population, irre-
spectively of whether values were calculated as peripheral 
or central blood pressure amplitudes. In our population, 
the sensitivities of cPP or pPP higher than 60 mmHg were 
as low as 10 % and 30 %, respectively.
The fi ndings of the present study have a number of rele-
vant implications for both clinical and scientifi c evaluation 
of in vivo arterial disease markers. First, the results show 
that a marker currently considered as gold standard (cfP-
WV) for disease detection has some drawbacks in the pres-
ence of atherosclerotic arterial diseases. Atherosclerotic 
vascular changes along the aortic and iliac arterial conduit 
may result in false low velocities, suggesting less or even 
absence of AOD. Even ABI, the gold standard assessment 
for PAD, may be not sensitive for atherosclerotic damage in 
case of non-signifi cant arterial stenosis. In this case, AOD 
can only be detected by noninvasive or invasive imaging, 
such as duplexsonography, intraarterial angiography or 
computed angiograms. In our patient selection, we diag-
nosed PAD prior to inclusion in the study. Second, our fi nd-
ings indicate that cut-off  values presented in current guide-
lines for the management of arterial hypertension, that 
recommend assessment of cfPWV in hypertensive patients 
[9], can only be advocated after exclusion of PAD and sug-
gest that single assessment such as cfPWV should not be 
performed in settings without proper medical knowledge 
or training. Third, devices for measurement of PWV diff er 
in their sensitivity to detect AOD and some methods might 
have advantages over the current gold standard.
Limitations
The sample size of our study was limited. More work is 
needed to evaluate the diff erences of cfPWV dependent 
on the stage and localization of the stenosis/obstruction.
Conclusions
In conclusion, in vivo markers of AOD do not off er satisfy-
ing sensitivities in presence of peripheral arterial disease 
and even the current gold standard to assess PWV has to 
be used with caution, specifi cally in PAD patients. Given 
that advanced age is an independent determinant of gen-
eralized atherosclerosis, markers of AOD in elderly pa-
tients have to be evaluated in relation to potential presence 
of an asymptomatic peripheral arterial disease due to its 
high prevalence in the aged population.
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